Information Provided By:
Fly News Breaks for July 10, 2015
XOMA
Jul 10, 2015 | 05:58 EDT
Piper Jaffray analyst Edward Tenthoff recommends shares of XOMA ahead of the Phase III trial results for gevokizumab in Behcet's uveitis. The stock offers a good risk/reward into the data, which could come any day, even after yesterday's 21% rally, Tenthoff tells investors in research note. He reiterates an Overweight rating on XOMA with an $8 price target. The antibody-based therapeutics company closed yesterday up 77c to $4.49.
News For XOMA From the Last 2 Days
There are no results for your query XOMA